Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
To elucidate the mechanism of liver metastasis of pancreatic cancer, we focused on thrombopoietin (TPO) and its receptor CD 110 in pancreatic cancer. In resected specimens of pancreatic cancer, high expression of CD110 was an independent poor prognostic factor and independent predictor of liver metastasis. Inhibition of CD110 expression in pancreatic cancer cells significantly reduced migration / invasion ability of pancreatic cancer cells. In CD110-positive pancreatic cancer cells, ERK and MYC were activated by TPO administration, and cell proliferation was increased. These results suggested that TPO - CD110 - ERK - MYC signal might be involved in liver metastasis in pancreatic cancer.
|